Marker Therapeutics, Inc.

News

TapImmune Prevails in Legal Dispute with Michael Gardner

…International Arbitration Tribunal Finds in Favor of TapImmune Inc., and Awards the Company $196,204 in Damages

SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIV), announces successful outcome of proceedings against Michael Gardner after almost 2 years of litigation.

The International Center for Dispute Resolution International Arbitration Tribunal has found that Mr. Gardner made numerous false representations, did not fully provide the services he was hired to perform and did not intend to perform them at the time he was hired.

Read More

TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board

…SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company’s scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St.

Read More

TapImmune Inc. is Pleased to Announce the Filing of New Intellectual Property Surrounding its Novel and Proprietary Platform Expression System PolyStart™

…New Technology Significantly Enhances the Presentation of Desired Peptides on the Surface of Cells for Targeting to the Immune System

SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has filed a new patent application for a novel technology platform designed to enhance the visibility of cancer or infected cells to a patient’s immune system, a critical aspect of an effective vaccine.

Read More

TapImmune Inc. is Pleased to Announce the Signing of an Exclusive Option Agreement for a New Phase 1 Clinical Program in Breast and Ovarian Cancer

…SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD), A clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease has signed an exclusive option agreement for a set of unique peptide epitopes targeting Folate Receptor Alpha in both breast cancer and ovarian cancer.

Folate receptor alpha is expressed in nearly 50% of breast cancers and in addition, over 95% of ovarian cancers, for which the only treatment options are surgery and chemotherapy, leaving a very important and urgent clinical need for a new therapeutic.

Read More

TapImmune Inc. To Present at 2014 Annual Roth Capital Growth Stock Conference

…Seattle, WA / ACCESSWIRE / March 5, 2014 / TapImmune Inc. (TPIVD), a clinical stage immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease, will be presenting at the Annual Roth Capital Growth Stock Conference on March 12 2014.

The conference is taking place at the Ritz Carlton Hotel in Dana Point, California March 9-12, 2014 and is one of the largest of its kind, attended by numerous emerging growth companies and their investors.

Read More

TapImmune Releases Positive Interim Data on Phase I Clinical Trial in HER2/neu+ Breast Cancer

…Results Meet Management’s Highest Expectations

SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes.

Read More

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

…SEATTLE–(BUSINESS WIRE)–

TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.

Dear Shareholders,

Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it. To address this, we now announce the completion of a corporate restructuring to attract the financial backing of some of the most respected names in life science to aid us in executing our product development plans and to provide fuel for our growth.

Read More

TapImmune Chairman and CEO, Glynn Wilson, Ph.D. Provides Corporate Update on Company Progress

…SEATTLE, WA / Feb 25, 2014 / ACCESSWIRE / TapImmune Inc. (TPIVD) Chairman and CEO, Glynn Wilson, Ph.D., has issued the following letter to the shareholders.

Dear Shareholders,
Over the past few years TapImmune has developed a strong scientific and clinical position in immunotherapy but has lacked the financial resources to fully leverage it.

Read More

Tapimmune Announces Development Of Advanced Immunotherapeutic Vaccine Expression And Delivery System

…TapImmune is pleased to announce development of a revolutionary cost effective immunotherapeutic vaccine expression and delivery system.

The novel platform is termed TapImmune’s PolyStart™ technology and has been strategically designed to directly enhance the immune system’s ability to stimulate either or BOTH cytotoxic killer and helper T-cell reactive proprietary peptides, known and expected to be associated with one, or more importantly, ANY cancer, infectious disease or bio-threat.

Read More

TapImmune Chairman Provides Corporate Update on Development Programs & Collaborations

…It is my pleasure to provide an update to existing and potentially new shareholders on the progress we have made over the past few months.

Highlights from the below detailed update include:

Positive progress at the MAYO clinic on the phase 1 HER2/neu clinical trial with interim results expected in the near term.

Read More